TY - JOUR
T1 - Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma
AU - Mehta-Shah, Neha
AU - Younes, Anas
N1 - Publisher Copyright:
© 2015.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma. Next-generation sequencing techniques have improved our understanding of the molecular pathways that may drive oncogenesis. Many novel classes of drugs are in development that may improve the treatment of DLBCL, either as single agents or in combination, that exploit their synergy to overcome resistance. We review the key novel targets and therapeutics in the treatment of DLBCL, including immunomodulatory agents and immunotherapy.
AB - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma. Next-generation sequencing techniques have improved our understanding of the molecular pathways that may drive oncogenesis. Many novel classes of drugs are in development that may improve the treatment of DLBCL, either as single agents or in combination, that exploit their synergy to overcome resistance. We review the key novel targets and therapeutics in the treatment of DLBCL, including immunomodulatory agents and immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84925260858&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2015.01.007
DO - 10.1053/j.seminhematol.2015.01.007
M3 - Review article
C2 - 25805592
AN - SCOPUS:84925260858
SN - 0037-1963
VL - 52
SP - 126
EP - 137
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - 2
ER -